亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efbemalenograstim alfa for prophylaxis in non–small cell lung cancer patients patients with chemotherapy-induced febrile neutropenia: A randomized, multicenter, exploratory clinical trial.

作者
Mengjie Li,Dingzhi Huang,Caixia Liu,Fengming Ran,Hai‐tao Lan,Jun Ge,Zheng Zhao,Chuangzhou Rao,Wei Zheng,Xiaoyong Tang,Tianhui Gao,Yong Mao,Wei Cui,Zhengguo Li
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (16_suppl): 8657-8657
标识
DOI:10.1200/jco.2026.44.16_suppl.8657
摘要

8657 Background: Neutropenia is a common dose-limiting chemotherapy toxicity, with its severity and duration impairing therapeutic efficacy. In NSCLC management, chemotherapy regimens with high risk febrile neutropenia (FN) are relatively uncommon. However, real-world data show suboptimal prophylactic granulocyte colony-stimulating factor (G-CSF) use in intermediate risk FN patients with additional risk factors. This study evaluated efbemalenograstim alfa's efficacy and safety in maintaining absolute neutrophil count (ANC) during chemotherapy cycles in such NSCLC patients. Methods: This was a randomized, multicenter, exploratory clinical trial (NCT06143735) enrolling NSCLC patients receiving intermediate risk FN chemotherapy with additional risk factors. Eligible patients were randomized 2:1 into two groups: primary prophylaxis group (Group A) received subcutaneous efbemalenograstim alfa (20 mg) 48±4 h post-each chemo cycle starting from Cycle 1; secondary prophylaxis group (Group B) initiated treatment only upon grade ≥3 neutropenia (per CTCAE v5.0) in the prior cycle. All patients completed at least four cycles of platinum-based chemotherapy. The primary endpoint was the incidence of grade ≥3 neutropenia in Cycle 1 between the two strategies. Secondary endpoints included FN incidence, grade ≥3 neutropenia in subsequent cycles, and the occurrence of adverse events (AEs) or serious adverse events (SAEs). Results: As of Dec 31, 2025, 99 patients were enrolled; 93 (median age: 69 years; 61.3% with ECOG 0–1; 90.3% male) received ≥1 platinum-based chemo cycle; 83 received ≥1 efbemalenograstim alfa dose. Specifically, 61 patients were assigned to Group A and 32 to Group B (n = 93). In the first treatment cycle, the incidence of grade ≥3 neutropenia was 19.7% (12/61) in Group A vs. 50.0% (16/32) in Group B, representing a relative risk reduction (RRR) of 60.6% (absolute risk reduction: 30.3%; p = 0.002). Across all treatment cycles, the cycle-specific cumulative incidence of grade ≥3 neutropenia was 16.2% (32/198) in Group A vs. 25.6% (32/125) in Group B (p = 0.0382). FN occurred in 2 patients in both groups. Regarding safety, the most common adverse events (AEs) were hematological toxicities in both groups, with a numerically lower incidence of anemia, leukopenia, neutropenia, and thrombocytopenia in Group A than in Group B. Grade ≥3 AEs (52.5% vs. 43.8%, p = 0.514) and efbemalenograstim alfa-related treatment-emergent adverse events (TRAEs, 31.1% vs. 22.7%, p = 0.587) did not differ significantly. Pain-related TRAEs (mainly ankle pain and neuropathic pain) were reported in only 6 patients (7.2%) overall, with most being grade 1–2 per CTCAE v5.0 criteria. Conclusions: Efbemalenograstim alfa effectively reduces the incidence of chemotherapy-induced neutropenia and presents a favorable safety profile. Clinical trial information: NCT06143735 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
现代的如容完成签到,获得积分10
2秒前
lyp完成签到 ,获得积分10
6秒前
7秒前
平和的狍子完成签到 ,获得积分10
9秒前
汉堡包的应助被breeze采纳,获得10
12秒前
Akim的应助被Yuantian采纳,获得30
13秒前
14秒前
乐正亦寒完成签到 ,获得积分10
20秒前
酷炫鹏煊完成签到 ,获得积分10
22秒前
学霸宇大王完成签到 ,获得积分10
27秒前
淡然葶完成签到 ,获得积分10
27秒前
黑早早完成签到,获得积分10
27秒前
谦让的沛芹完成签到,获得积分10
29秒前
30秒前
31秒前
32秒前
35秒前
42秒前
43秒前
liugm发布了新的文献求助10
44秒前
toxin37完成签到 ,获得积分10
46秒前
小井盖完成签到 ,获得积分0
47秒前
48秒前
含蓄的芝麻完成签到,获得积分10
49秒前
陌陌完成签到 ,获得积分10
50秒前
菌菌的应助被郦稀采纳,获得30
53秒前
56秒前
煊陌完成签到 ,获得积分10
59秒前
xiaoyin完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
Lifel完成签到,获得积分10
1分钟前
1分钟前
1分钟前
A水暖五金批发张哥完成签到,获得积分10
1分钟前
Ni完成签到 ,获得积分10
1分钟前
云墨完成签到 ,获得积分10
1分钟前
1分钟前
椰子云发布了新的文献求助10
1分钟前
学术雷锋发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158598
求助须知:如何正确求助?哪些是违规求助? 9554358
关于积分的说明 21719087
捐赠科研通 7748128
什么是DOI,文献DOI怎么找? 3427032
关于科研通互助平台的介绍 2551902
邀请新用户注册赠送积分活动 2471277